Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
CagriSema: A Dual-Target Therapy for Obesity and Type 2 Diabetes Novo Nordisk unveiled the Phase 3 results from the REDEFINE 1 and REDEFINE 2 studies of CagriSema, a fixed-dose combination of cagrilintide (an amylin analog) and semaglutide
In newly diagnosed type 2 diabetic patients, a 3-month trial showed significant reductions in hemoglobin A1c (HbA1c), fasting blood glucose, and postprandial glucose levels, comparable to metformin
Theranostics 11 , 22472262 (2021)
Those discussions should be treated with caution
Strategies for managing this period include maintaining close communication with your healthcare provider about side effects, using all available anti-nausea strategies proactively rather than reactively, accepting that some temporary discomfort accompanies effective treatment, focusing on the progress already made rather than the challenges remaining, and remembering that 85% of patients report minimal side effects by month four
Please talk with your pharmacy directly about insurance coverage
US$ 21.69
US$ 22.44
US$ 29.00
US$ 20.28
